Discontinued — last reported Q3 '25
West Pharmaceutical Services Deferred Tax Assets decreased by 1.3% to $22.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.6%, from $21.30M to $22.70M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows an upward trend with a 17.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase can signal future tax efficiency or the utilization of past losses, while a decrease may indicate the realization of those benefits.
These are assets on the balance sheet that represent future tax savings resulting from temporary differences between the...
Common in large, capital-intensive companies; peers with significant R&D spending often have large deferred tax assets from tax credits.
deferred_tax_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.20M | $11.60M | $4.90M | $3.30M | $1.20M | $16.60M | $14.30M | $14.50M | $15.40M | $16.50M | $12.70M | $12.70M | $13.70M | $9.40M | $20.50M | $21.30M | $23.00M | $22.80M | $23.00M | $22.70M |
| QoQ Change | — | -4.9% | -57.8% | -32.7% | -63.6% | >999% | -13.9% | +1.4% | +6.2% | +7.1% | -23.0% | +0.0% | +7.9% | -31.4% | +118.1% | +3.9% | +8.0% | -0.9% | +0.9% | -1.3% |
| YoY Change | — | — | — | — | -90.2% | +43.1% | +191.8% | +339.4% | >999% | -0.6% | -11.2% | -12.4% | -11.0% | -43.0% | +61.4% | +67.7% | +67.9% | +142.6% | +12.2% | +6.6% |